Katherine A Murphy1, Brian A Harsch2, Chastity L Healy1, Sonal S Joshi1, Shue Huang2, Rachel E Walker2, Brandon M Wagner1, Katherine M Ernste1, Wei Huang3, Robert C Block4, Casey D Wright5, Nathan Tintle6, Brian C Jensen3, Quinn S Wells7, Gregory C Shearer2, Timothy D O'Connell1. 1. Department of Integrative Biology and Physiology, University of Minnesota, 3-141 CCRB, 2231 6th Street SE, Minneapolis, MN 55414, USA. 2. Department of Nutritional Sciences, The Pennsylvania State University, 110 Chandlee Laboratory, University Park, PA 16802, USA. 3. Division of Cardiology and McAllister Heart Institute, University of North Carolina, Chapel Hill, NC, USA. 4. Department of Public Health Sciences, University of Rochester, NY, USA. 5. Inanovate Inc., Sioux Falls, SD, USA. 6. Department of Statistics, Dordt University, Sioux Center, IA, USA. 7. Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
AIMS: Free fatty acid receptor 4 (Ffar4) is a G-protein-coupled receptor for endogenous medium-/long-chain fatty acids that attenuates metabolic disease and inflammation. However, the function of Ffar4 in the heart is unclear. Given its putative beneficial role, we hypothesized that Ffar4 would protect the heart from pathologic stress. METHODS AND RESULTS: In mice lacking Ffar4 (Ffar4KO), we found that Ffar4 is required for an adaptive response to pressure overload induced by transverse aortic constriction (TAC), identifying a novel cardioprotective function for Ffar4. Following TAC, remodelling was worsened in Ffar4KO hearts, with greater hypertrophy and contractile dysfunction. Transcriptome analysis 3-day post-TAC identified transcriptional deficits in genes associated with cytoplasmic phospholipase A2α signalling and oxylipin synthesis and the reduction of oxidative stress in Ffar4KO myocytes. In cultured adult cardiac myocytes, Ffar4 induced the production of the eicosapentaenoic acid (EPA)-derived, pro-resolving oxylipin 18-hydroxyeicosapentaenoic acid (18-HEPE). Furthermore, the activation of Ffar4 attenuated cardiac myocyte death from oxidative stress, while 18-HEPE rescued Ffar4KO myocytes. Systemically, Ffar4 maintained pro-resolving oxylipins and attenuated autoxidation basally, and increased pro-inflammatory and pro-resolving oxylipins, including 18-HEPE, in high-density lipoproteins post-TAC. In humans, Ffar4 expression decreased in heart failure, while the signalling-deficient Ffar4 R270H polymorphism correlated with eccentric remodelling in a large clinical cohort paralleling changes observed in Ffar4KO mice post-TAC. CONCLUSION: Our data indicate that Ffar4 in cardiac myocytes responds to endogenous fatty acids, reducing oxidative injury, and protecting the heart from pathologic stress, with significant translational implications for targeting Ffar4 in cardiovascular disease. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Free fatty acid receptor 4 (Ffar4) is a G-protein-coupled receptor for endogenous medium-/long-chain fatty acids that attenuates metabolic disease and inflammation. However, the function of Ffar4 in the heart is unclear. Given its putative beneficial role, we hypothesized that Ffar4 would protect the heart from pathologic stress. METHODS AND RESULTS: In mice lacking Ffar4 (Ffar4KO), we found that Ffar4 is required for an adaptive response to pressure overload induced by transverse aortic constriction (TAC), identifying a novel cardioprotective function for Ffar4. Following TAC, remodelling was worsened in Ffar4KO hearts, with greater hypertrophy and contractile dysfunction. Transcriptome analysis 3-day post-TAC identified transcriptional deficits in genes associated with cytoplasmic phospholipase A2α signalling and oxylipin synthesis and the reduction of oxidative stress in Ffar4KO myocytes. In cultured adult cardiac myocytes, Ffar4 induced the production of the eicosapentaenoic acid (EPA)-derived, pro-resolving oxylipin 18-hydroxyeicosapentaenoic acid (18-HEPE). Furthermore, the activation of Ffar4 attenuated cardiac myocyte death from oxidative stress, while 18-HEPE rescued Ffar4KO myocytes. Systemically, Ffar4 maintained pro-resolving oxylipins and attenuated autoxidation basally, and increased pro-inflammatory and pro-resolving oxylipins, including 18-HEPE, in high-density lipoproteins post-TAC. In humans, Ffar4 expression decreased in heart failure, while the signalling-deficient Ffar4 R270H polymorphism correlated with eccentric remodelling in a large clinical cohort paralleling changes observed in Ffar4KO mice post-TAC. CONCLUSION: Our data indicate that Ffar4 in cardiac myocytes responds to endogenous fatty acids, reducing oxidative injury, and protecting the heart from pathologic stress, with significant translational implications for targeting Ffar4 in cardiovascular disease. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Jinghai Chen; Gregory C Shearer; Quanhai Chen; Chastity L Healy; April J Beyer; Vijaya B Nareddy; A Martin Gerdes; William S Harris; Timothy D O'Connell; Dajun Wang Journal: Circulation Date: 2011-01-31 Impact factor: 29.690
Authors: Fawzi A Babiker; Daniel Lips; Rainer Meyer; Els Delvaux; Pieter Zandberg; Ben Janssen; Guillaume van Eys; Christian Grohé; Pieter A Doevendans Journal: Arterioscler Thromb Vasc Biol Date: 2006-04-20 Impact factor: 8.311
Authors: Julie A Eclov; Qingwen Qian; Rebecca Redetzke; Quanhai Chen; Steven C Wu; Chastity L Healy; Steven B Ortmeier; Erin Harmon; Gregory C Shearer; Timothy D O'Connell Journal: J Lipid Res Date: 2015-10-04 Impact factor: 5.922
Authors: David S Siscovick; Thomas A Barringer; Amanda M Fretts; Jason H Y Wu; Alice H Lichtenstein; Rebecca B Costello; Penny M Kris-Etherton; Terry A Jacobson; Mary B Engler; Heather M Alger; Lawrence J Appel; Dariush Mozaffarian Journal: Circulation Date: 2017-03-13 Impact factor: 29.690
Authors: Brian D Hudson; Bharat Shimpukade; Amanda E Mackenzie; Adrian J Butcher; John D Pediani; Elisabeth Christiansen; Helen Heathcote; Andrew B Tobin; Trond Ulven; Graeme Milligan Journal: Mol Pharmacol Date: 2013-08-26 Impact factor: 4.436
Authors: Virginia M Stone; Shalinee Dhayal; Katy J Brocklehurst; Carol Lenaghan; Maria Sörhede Winzell; Mårten Hammar; Xiufeng Xu; David M Smith; Noel G Morgan Journal: Diabetologia Date: 2014-03-25 Impact factor: 10.122
Authors: Timothy D O'Connell; Katherine A Murphy; Naixin Zhang; Sara J Puccini; Chastity L Healy; Brian A Harsch; Michael J Zhang; Gregory C Shearer Journal: Physiology (Bethesda) Date: 2022-08-09
Authors: Derek Strassheim; Timothy Sullivan; David C Irwin; Evgenia Gerasimovskaya; Tim Lahm; Dwight J Klemm; Edward C Dempsey; Kurt R Stenmark; Vijaya Karoor Journal: Cells Date: 2021-11-29 Impact factor: 7.666